Tharimmune, Inc. Enters Material Definitive Agreement

Ticker: CNTN · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1861657

Tharimmune, INC. 8-K Filing Summary
FieldDetail
CompanyTharimmune, INC. (CNTN)
Form Type8-K
Filed DateOct 6, 2025
Risk Levelmedium
Pages1
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, corporate-action

TL;DR

Tharimmune just signed a big deal, filing an 8-K on Oct 1st.

AI Summary

On October 1, 2025, Tharimmune, Inc. entered into a material definitive agreement. The company, formerly known as Hillstream BioPharma Inc., is incorporated in Delaware and has its principal executive offices in Red Bank, NJ.

Why It Matters

This filing indicates a significant development for Tharimmune, Inc., potentially involving a new partnership, acquisition, or other crucial business transaction.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities, the specifics of which are not detailed in this initial filing.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Tharimmune, Inc. on October 1, 2025?

The filing does not specify the nature of the material definitive agreement, only that one was entered into on October 1, 2025.

What was Tharimmune, Inc. formerly known as?

Tharimmune, Inc. was formerly known as Hillstream BioPharma Inc.

In which state is Tharimmune, Inc. incorporated?

Tharimmune, Inc. is incorporated in Delaware.

What is the principal executive office address for Tharimmune, Inc.?

The principal executive office address for Tharimmune, Inc. is 34 Shrewsbury Avenue, Suite 1C, Red Bank, NJ 07701.

What is the SEC file number for Tharimmune, Inc.?

The SEC file number for Tharimmune, Inc. is 001-41210.

Filing Stats: 388 words · 2 min read · ~1 pages · Grade level 11.5 · Accepted 2025-10-06 08:24:56

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 6, 2025 Tharimmune, Inc. /s/ Sireesh Appajosyula Sireesh Appajosyula Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing